Amicus Therapeutics: A Biopharmaceutical Company For the People

The Cranbury, New Jersey-based Amicus Therapeutics opened its doors to the public in 2007. The medical research organization focuses on rare and orphan diseases, specializing in the study of lysosomal storage disorders. The put much concentration on developing enzyme replacement therapies. In 2008, they were doing so well at what they did that they were able to expand to another research facility in San Diego. In 2010, it received a huge boost two sizeable grants: A $500,000 grant from The Michael J. Fox Foundation and a $210,300 grant from the Alzheimer’s Drug Discovery Foundation.

amicus1

The donations of 2010 seem to spur it even to greater heights in the following years. In 2013, they acquired and absorbed a primary medical research company, Callidus Biopharma. In 2015, they grew again after acquiring and absorbing another primary competitor, Scioderm. They are recognized as being at the top of this particular medical research field. However, although Amicus Therapeutics is more than capable of research and development, it is not able to mass manufacture these things. To do so, if often contracts out to various pharmaceutical manufacturers and distributors.

 

But Amicus is very proud to be the primary medical source for a host of orphan and rare diseases. They are especially proud of migalastat, a medicine that has been shown to effectively treat patients in late-stage Fabry disease (http://www.phillypurge.com/2017/08/02/amicus-therapeutics-the-fight-against-the-rare-diseases/). Amicus Therapeutics has been led by CEO John Crowley since 2005. In 2010 he also became the chairman of its board. To other extremely important leadership roles at Amicus are Chief Scientific Officer and Director of Exploratory Biology. These roles were assumed in 2010 by David Lockhart and Brandon Wustman, respectively. All three of these men are completely dedicated to improving the quality of life of patients and doctors in the rare disease community. You can find more information about Amicus and its work at.

More about Amicus Therapeutics at Marketwatch | IndeedCrunchBase

Leave a Reply

Your email address will not be published. Required fields are marked *